Recurrent Adult Acute Myeloid Leukemia (DBCOND0028883)

Identifiers

Synonyms

Recurrent Acute Myeloid Leukemia, Adult

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT02593123	Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis	Filgrastim Mycophenolate mofetil Sargramostim	treatment	2	completed
NCT02727803	Personalized NK Cell Therapy in CBT	Activated natural killer cell therapy Aloe vera leaf Ascorbic acid Busulfan CD-16 NK-92 cells Clofarabine Cyclophosphamide Fludarabine Glycerin Mechlorethamine Natural Killer Cell Nicotinamide Rituximab Vitamin A	treatment	2	recruiting
NCT00489203	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer	Beclomethasone dipropionate Methotrexate Tacrolimus	supportive_care	2	completed
NCT01233921	Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	Palifermin	supportive_care	Not Available	completed
NCT03519984	EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia	Cytarabine SEphB4-HSA Vincristine	treatment	1	terminated
NCT03513484	Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia	Azacitidine Nintedanib Tyrosine	treatment	1	active_not_recruiting
NCT01342887	Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Cyclosporine Etoposide Mitoxantrone Pravastatin	treatment	1 / 2	terminated
NCT01841333	PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant	Glasdegib	treatment	2	completed
NCT00006251	Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT00890747	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy	Sunitinib	treatment	1	completed
NCT05672147	CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia	No drug interventions	treatment	1	recruiting
NCT01729845	Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes	Beta-D-Glucose Cytarabine Decitabine Etoposide Mitoxantrone	treatment	1 / 2	completed
NCT00095797	XK469R in Treating Patients With Refractory Hematologic Cancer	No drug interventions	treatment	1	completed
NCT00470197	Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia	Alvocidib Cytarabine Mitoxantrone	treatment	1	completed
NCT02921061	Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS	Cladribine Cytarabine Decitabine Filgrastim Mitoxantrone	treatment	1 / 2	completed
NCT02583893	Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia	Cytarabine Etoposide Mitoxantrone Sirolimus	basic_science	2	completed
NCT01177371	High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma	Busulfan Cyclophosphamide Cyclosporine Methotrexate Methylprednisolone Methylprednisolone hemisuccinate	treatment	2	completed
NCT01558778	Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	Not Available	withdrawn
NCT00666588	Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia	Bortezomib Bortezomib D-mannitol Cytarabine Etoposide Idarubicin	treatment	2	completed
NCT02323607	Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations	Cytarabine Daunorubicin Decitabine Pacritinib	treatment	1	completed
NCT01550185	Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia	Eltrombopag	treatment	1	terminated
NCT01907815	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia	Trametinib Uprosertib	treatment	2	terminated
NCT00025415	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction	Imatinib	treatment	1	completed
NCT00118352	Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Alemtuzumab Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT00703300	Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia	2'-Deoxycytidine Bortezomib Bortezomib D-mannitol Decitabine	treatment	1	completed
NCT02144675	Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia	Choline magnesium trisalicylate Cytarabine Idarubicin	treatment	2	completed
NCT00062075	Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Romidepsin	treatment	2	completed
NCT00351975	Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases	Azacitidine Belinostat	treatment	1	completed
NCT00093470	Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission	Tipifarnib	treatment	3	completed
NCT00005942	Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy	Daunorubicin Semaxanib	treatment	1 / 2	completed
NCT06329999	A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML	No drug interventions	treatment	Not Available	recruiting
NCT00005799	Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer	Cyclosporine Fludarabine Mycophenolate mofetil Therapeutic allogeneic lymphocytes	treatment	Not Available	completed
NCT03537599	Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant	Daratumumab	treatment	1 / 2	completed
NCT01083706	Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant	Azacitidine	treatment	2	completed
NCT00006213	BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia	BMS-214662	treatment	1	completed
NCT01384513	A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies	Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00093418	S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia	Tipifarnib	treatment	2	completed
NCT02299518	Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Cytarabine Escitalopram Etoposide Mitoxantrone Selinexor	treatment	1	completed
NCT01168219	Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia	Aloe vera leaf Ascorbic acid Azacitidine Busulfan Fludarabine Glycerin Methopterin Methotrexate Nicotinamide Tacrolimus Vitamin A	treatment	2	completed
NCT02791919	Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia	Adavosertib Cytarabine Filgrastim Fludarabine	treatment	1	withdrawn
NCT00895934	Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML	Azacitidine Gemtuzumab ozogamicin Vorinostat	treatment	1 / 2	completed
NCT00863434	Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease	Clofarabine Cytarabine Filgrastim	treatment	2	terminated
NCT01839916	Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Therapeutic allogeneic lymphocytes	treatment	2	completed
NCT00101296	Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Tipifarnib	treatment	1	completed
NCT02044796	Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes	Cladribine Cytarabine Filgrastim Mitoxantrone	treatment	1 / 2	completed
NCT00078858	Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT00014235	Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT00313586	Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia	Azacitidine Entinostat	treatment	2	completed
NCT01093586	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Cyclosporine Methylprednisolone Methylprednisolone hemisuccinate Mycophenolate mofetil	treatment	2	completed
NCT01757639	Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia	Ipilimumab	treatment	1	completed
NCT01246622	Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Cytarabine Lenalidomide	treatment	1	completed
NCT01249430	Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Azacitidine Cytarabine Etoposide Mitoxantrone	treatment	1	completed
NCT00278330	Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia	Alvocidib Vorinostat	treatment	1	completed
NCT02381548	Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia	Adavosertib Belinostat	treatment	1	terminated
NCT00098826	SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes	Ispinesib	treatment	1	completed
NCT00027820	Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT00839982	Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS	Clofarabine Cytarabine	treatment	1 / 2	completed
NCT00305773	Vorinostat in Treating Patients With Acute Myeloid Leukemia	Vorinostat	treatment	2	completed
NCT01529827	Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Fludarabine Melphalan Methotrexate Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00588991	Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders	Carboplatin Topotecan Veliparib	treatment	1	active_not_recruiting
NCT01199562	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant	Foscarnet Ganciclovir Valganciclovir	Not Available	Not Available	completed
NCT02333162	Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant	Fludarabine Melphalan Mycophenolate mofetil Tacrolimus	treatment	1	recruiting
NCT00445744	Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome	Busulfan Cyclophosphamide Methotrexate Tacrolimus	treatment	Not Available	completed
NCT01858740	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children	Fludarabine Methopterin Methotrexate Tacrolimus Thiotepa Tromethamine	treatment	2	completed
NCT01159067	Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload	Deferasirox	supportive_care	2	terminated
NCT01758367	Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation	Decitabine	treatment	1 / 2	unknown_status
NCT01798901	AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia	2'-Deoxycytidine AR-42 Decitabine	treatment	1	completed
NCT01640301	Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant	Aldesleukin Cyclophosphamide Fludarabine	treatment	1 / 2	terminated
NCT02049801	MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Binimetinib Cytarabine Idarubicin	treatment	1	terminated
NCT01707004	Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Azacitidine Busulfan Cyclophosphamide Decitabine Filgrastim Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00060372	Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer	Ipilimumab Therapeutic allogeneic lymphocytes	treatment	1	completed
NCT01031368	Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia	Clofarabine Cytarabine Dilanubicel Filgrastim	treatment	1	completed
NCT01801046	Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia	Cytarabine Mitoxantrone	treatment	1	terminated
NCT00040846	Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies	Alemtuzumab Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT00459212	GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia	GTI-2040	treatment	1	completed
NCT00077181	3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies	Cytarabine Triapine	treatment	1	completed
NCT00408681	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant	Lithium carbonate	supportive_care	Not Available	completed
NCT02122081	Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Cyclophosphamide Methotrexate Tacrolimus	treatment	1	completed
NCT00540995	Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer	Beta-D-Glucose Busulfan Etoposide	treatment	1 / 2	terminated
NCT01861314	Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia	Bortezomib Bortezomib D-mannitol Decitabine Sorafenib	treatment	1	active_not_recruiting
NCT01523223	Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies	Therapeutic allogeneic lymphocytes	treatment	1	completed
NCT00098423	Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes	Cytarabine Tanespimycin	treatment	1	completed
NCT00357708	Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases	2'-Deoxycytidine Decitabine Vorinostat	treatment	1	completed
NCT02353143	Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia	No drug interventions	treatment	1	terminated
NCT01904643	Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Cytarabine Etoposide Lenalidomide Mitoxantrone	treatment	1	terminated
NCT01869803	Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia	Gemtuzumab ozogamicin	Not Available	Not Available	approved_for_marketing
NCT00005064	PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome	Bortezomib Bortezomib D-mannitol	treatment	1	completed
NCT02446964	Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	1	active_not_recruiting
NCT02316964	Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	2'-Deoxycytidine Aldesleukin Decitabine Natural Killer Cell	treatment	1	completed
NCT00101179	MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia	Azacitidine Entinostat	treatment	1	completed
NCT01307579	Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia	Caspofungin Fluconazole	supportive_care	3	completed
NCT00070551	GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia	Cytarabine GTI-2040	treatment	1	completed
NCT01876953	Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia	Cytarabine Dasatinib Idarubicin	treatment	1 / 2	terminated
NCT00392353	Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia	Azacitidine Vorinostat	treatment	1 / 2	active_not_recruiting
NCT00008177	Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT01564277	Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies	Allopurinol Rasburicase	treatment	2	terminated
NCT01253447	AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	No drug interventions	treatment	2	completed
NCT01607645	Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS	2'-Deoxycytidine Cytarabine Decitabine Idarubicin	treatment	2	terminated
NCT01044745	Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Rituximab Tacrolimus	treatment	2	terminated
NCT01527045	Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies	Atorvastatin Cyclosporine Fludarabine Mycophenolate mofetil	prevention	2	completed
NCT00052598	Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant	Aldesleukin Therapeutic allogeneic lymphocytes	treatment	1 / 2	terminated
NCT00357305	Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders	Cytarabine Etoposide Vorinostat	treatment	1	completed
NCT02030405	Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Ixazomib	treatment	2	terminated
NCT00462605	MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia	Entinostat Sargramostim	treatment	2	completed
NCT01664897	Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Erlotinib	treatment	2	completed
NCT01768897	CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Cytarabine Devimistat Lipoic acid Mitoxantrone	treatment	1	completed
NCT00799461	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications	No drug interventions	supportive_care	3	completed
NCT01159028	Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS	Cytarabine Prexigebersen	treatment	1	completed
NCT01548911	Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia	Gemtuzumab ozogamicin	treatment	2	withdrawn
NCT00089011	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT03146871	Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent	Azacitidine Decitabine SEphB4-HSA	treatment	2	terminated
NCT00079378	Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	2'-Deoxycytidine Decitabine Valproic acid	treatment	1	completed
NCT02337478	Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Vincristine	treatment	2	terminated
NCT01835288	Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Arsenic trioxide Arsenous acid	treatment	2	withdrawn
NCT00856388	Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Fludarabine Melphalan	treatment	Not Available	completed
NCT01174888	Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia	Beta-D-Glucose Bortezomib Bortezomib D-mannitol Cytarabine Etoposide Midostaurin Mitoxantrone	treatment	1	completed
NCT00588809	Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia	Selumetinib	treatment	2	completed
NCT01127009	Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia	Beta-D-Glucose Bortezomib Bortezomib D-mannitol Cytarabine Etoposide Mitoxantrone	treatment	1	completed
NCT02204085	A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia	Decitabine GO-203-2C	treatment	1 / 2	active_not_recruiting
NCT00988715	Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT01588015	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	1	completed
NCT00357032	PXD101 in Treating Patients With Acute Myeloid Leukemia	Belinostat	treatment	2	completed
NCT02728700	Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT	Mycophenolate mofetil Sirolimus	prevention	1	terminated
NCT00003875	Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia	Aldesleukin Busulfan Etoposide	treatment	2	completed
NCT01076270	Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Filgrastim Plerixafor	treatment	Not Available	terminated
NCT01139970	Veliparib and Temozolomide in Treating Patients With Acute Leukemia	Temozolomide Veliparib	treatment	1	active_not_recruiting
NCT01130506	Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	Cytarabine Decitabine Vorinostat	treatment	1	completed
NCT00331513	Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes	Idarubicin Vorinostat	treatment	1	completed
NCT00068718	Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant	Therapeutic allogeneic lymphocytes	treatment	1 / 2	completed
NCT01872819	Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay	No drug interventions	treatment	Not Available	completed
NCT02581917	Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia	No drug interventions	Not Available	Not Available	completed
NCT01820624	Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Lithium carbonate Tretinoin	treatment	1	completed
NCT02105116	AML Therapy With Irradiated Allogeneic Cells	Cytarabine Filgrastim Fludarabine	treatment	Not Available	terminated
NCT00084916	CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase	Menthol Temsirolimus	treatment	2	completed
NCT00016016	Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia	Alvocidib Cytarabine Mitoxantrone	treatment	1 / 2	completed
NCT01519596	Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy	No drug interventions	supportive_care	Not Available	completed
NCT01870596	Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia	Cytarabine MK-8776	treatment	2	completed
NCT02070458	Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia	Cytarabine Etoposide Ixazomib Mitoxantrone	treatment	1	completed
NCT01132586	Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia	Cytarabine Idarubicin Lenalidomide	treatment	1	completed
NCT00602225	Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Clofarabine Cytarabine Filgrastim	treatment	1 / 2	completed
NCT00387426	Sunitinib in Treating Patients With Idiopathic Myelofibrosis	Sunitinib	treatment	2	terminated
NCT00119366	Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	terminated
NCT01273766	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies	Deferasirox	supportive_care	2	completed
NCT00383474	Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase	Bortezomib Bortezomib D-mannitol Tipifarnib	treatment	1	completed
NCT01787474	Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Cytarabine Filgrastim Fludarabine Natural Killer Cell	treatment	1	completed
NCT02635074	Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Cytarabine Ibrutinib Idarubicin	treatment	1	terminated
NCT00860574	Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia	Fludarabine Methotrexate Tacrolimus Treosulfan	treatment	2	completed
NCT03017820	VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma	Cemiplimab Cyclophosphamide Human interferon beta Sodium iodide	treatment	1	recruiting
NCT00052520	Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation	Aldesleukin Therapeutic allogeneic lymphocytes	treatment	1 / 2	completed
NCT00049582	Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia	2'-Deoxycytidine Decitabine	treatment	1	terminated
NCT00101231	Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	Alvocidib	treatment	1	terminated
NCT00012376	Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer	Bryostatin 1 Sargramostim	treatment	1	completed
NCT01849276	Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML	Cytarabine Metformin	treatment	1	terminated
NCT02094794	Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML	Cyclophosphamide Etoposide	treatment	2	recruiting
NCT02484391	CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma	Cytarabine Devimistat Lipoic acid Mitoxantrone	treatment	1	completed
NCT00039091	Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer	Ipilimumab	treatment	1	terminated
NCT00275080	Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia	2'-Deoxycytidine Decitabine Vorinostat	treatment	1	completed
NCT00131989	Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	Sorafenib	treatment	1	completed
NCT00634244	Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Alvocidib Carboplatin Cytarabine Etoposide Mitoxantrone Sirolimus Topotecan	treatment	2	completed
NCT01839240	Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia	Azacitidine Cytarabine Mitoxantrone	treatment	1	completed
NCT00322101	Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia	Busulfan Cyclophosphamide Cyclosporine Fludarabine Methotrexate Mycophenolate mofetil Tacrolimus	treatment	3	completed
NCT00536601	High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors	Busulfan Carboplatin Carmustine Cyclophosphamide Etoposide Melphalan Thiotepa	treatment	Not Available	completed
NCT01159301	Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia	Entinostat Sorafenib	treatment	1	terminated
NCT02129101	Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies	Azacitidine Decitabine Sonidegib	treatment	1	completed
NCT00105001	Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Sirolimus Tacrolimus	treatment	2	completed
NCT00087204	Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	Becatecarin Rebeccamycin	treatment	1	completed
NCT01235572	Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy	No drug interventions	health_services_research	2	completed
NCT01300572	Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	Cyclosporine Fludarabine Indium Mycophenolate mofetil	treatment	1	completed
NCT00103272	17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer	Bortezomib Bortezomib D-mannitol Tanespimycin	treatment	1	terminated
NCT00017472	Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia	Apolizumab	treatment	1	completed
NCT01555268	Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia	Cytarabine Trebananib	treatment	1	completed
NCT00301769	SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia	SJG-136	treatment	1	terminated
NCT00795769	Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant	Ondansetron	supportive_care	2	completed
NCT02019069	CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	Cytarabine Daunorubicin	treatment	2	completed
NCT00217646	Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	Sorafenib	treatment	1	completed
NCT01427881	Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies	Busulfan Cyclophosphamide Cyclosporine Fludarabine	treatment	2	completed
NCT02159495	Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm	Cyclophosphamide Fludarabine	treatment	1	active_not_recruiting
NCT01056614	Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Fludarabine Methotrexate Tacrolimus	treatment	2	completed
NCT01652014	Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	withdrawn
NCT01869114	Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy	Azacitidine Sirolimus	treatment	2	active_not_recruiting
NCT01260714	Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia	Azacitidine Beta-D-Glucose Etoposide Mitoxantrone	treatment	1	terminated
NCT01789255	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies	Cyclosporine Methotrexate Tacrolimus Vorinostat	supportive_care	2	completed
NCT01760655	Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies	1,4-Butanediol Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus Therapeutic allogeneic lymphocytes	treatment	2	completed
NCT00475150	Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	Cediranib	treatment	2	completed
NCT02666950	WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome	Adavosertib Cytarabine	treatment	2	completed
NCT00301938	7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes	7-Hydroxystaurosporine Perifosine	treatment	1	completed
NCT01041443	5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes	5-fluoro-2'-deoxycytidine Tetrahydrouridine	treatment	1	completed